Recognan (citicoline) prescribing in cerebrovascular diseases and type 2 diabetes mellitus patients

Close metadata

Recommended articles:

Identifying the neurostimulation target for treatment of cognitive impairment in aging and early cerebral small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):34-41

Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):57-62

Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):82-87

Cerebral hemodynamic disorders in patients with schizophrenia with concomitant metabolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):80-85

Prevalence of cognitive impairment in older adults in the Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Causes of hospital mortality in adults based on medical certificates of death. Russian Journal of Preventive Medicine. 2024;(3):7-13

Optimizing the treatment of diabetic ketoacidosis. Russian Journal of Anesthesiology and Reanimatology. 2024;(2):67-77

Mortality from cerebrovascular diseases in the Russian Federation before and during the COVID-19 epidemy: regional differences. Russian Journal of Preventive Medicine. 2024;(4):12-17

Modern issues of lung tuberculosis and diabetes mellitus on the tobacco consumption background in the world and the Russian Federation. Russian Journal of Preventive Medicine. 2024;(4):97-102

In a number of clinical studies, Recognan (citicoline) has demonstrated its effectiveness in patients with ischemic stroke, traumatic brain injury, cognitive disorders of various origins, in the complex therapy of asthenic and anxiety-depressive disorders, showing neuroprotective and neuropreparative properties. In recent years, emphasis has been placed on citicoline appointment in the complex therapy of patients with type 2 diabetes mellitus (DM2). In experimental (induced DM2) and clinical studies of patients with cerebrovascular diseases (CVD) and DM2, the effectiveness of Recogan (citicoline) against diabetic retinopathy and diabetic polyneuropathy in more significant clinical changes and negative dynamics absence of important laboratory parameters (blood glucose levels) in acute and stroke recovery periods in patients with DM2. The analysis of research materials allows Recogan to recommend to patients with CVD and DM2.

Keywords:

cerebrovascular diseases

cognitive impairment

diabetes mellitus

diabetic peripheral neuropathy

citicoline

Recognan

Authors:

Shavlovskaya O.A.

International University of Restorative Medicine

SPIN RSCI: 5300-4282
ORCID: 0000-0003-3726-0730

Received:

06.08.2024

Accepted:

07.08.2024

List of references:

Plataras C, Taskiris S, Angelogianni P. Effect of CDP-choline on brain acetylcholinesterase and Na+/K+-ATPase in adult rats. Clin Biochem. 2000;33:351-357. https://doi.org/10.1016/s0009-9120(00)00084-9
Secades J, Garery P. Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75(s05):S1-S89. https://doi.org/10.33588/rn.75s05.2022311
Shavlovskaya OA, Bokova IA. Recognan (citicoline) efficacy and safety in cognitive impairment correction of various nosological forms. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):22-28. (In Russ.). https://doi.org/10.17116/jnevro202312311122
Shavlovskaya OA. The assessment of the efficacy of citicoline in the early and recovery stages of stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6):93-97. (In Russ.). https://doi.org/10.17116/jnevro20161166193-97
Shavlovskaya OA. Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):43-47. (In Russ.). https://doi.org/10.17116/jnevro202412406143
Shavlovskaya OA, Bokova IA. Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3):57-62. (InRuss.). https://doi.org/10.17116/jnevro202412403157
Ahlawat A, Sharma S. A new promising simultaneous approach for attenuating type II diabetes mellitus induced neuropathic pain in rats: iNOS inhibition and neuroregeneration. Eur J Pharmacol. 2018;818:419-428. https://doi.org/10.1016/j.ejphar.2017.11.010
Tyurenkov IN, Kurkin DV, Bakulin DA, et al. Cerebroprotective activity of metformin, gosogliptin, citicoline and a novel GPR119 agonist in cerebral ischemia under experimental diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(12-2):53-59. (In Russ.). https://doi.org/10.17116/jnevro201711712253-59
Safavi M, Hosseini-Sharifabad A, Seyed-Yousefi Y, Rabbani M. protective effects of citicoline and benfotiamine each alone and in combination on streptozotocin-induced memory impairment in mice. Clin Psychopharmacol Neurosci. 2020;18(1):81-92. https://doi.org/10.9758/cpn.2020.18.1.81
Bogdanov P, Sampedro J, Solà-Adell C, et al. Effects of liposomal formulation of citicoline in experimental diabetes-induced retinal neurodegeneration. Int J Mol Sci. 2018;19(8):2458. https://doi.org/10.3390/ijms19082458
García-López C, García-López V, Matamoros JA, et al. The role of citicoline and coenzyme Q10 in retinal pathology. Int J Mol Sci. 2023;24:5072. https://doi.org/10.3390/ijms24065072
Liu Y, Li N, Ran X-W. Clinical effect of ligustrazine combined with citicoline for treatment of diabetic peripheral neuropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008;28(7):606-609.
Bogolepova AN, Burd SG, Lebedeva AV, Kovalenko YeA. Opyt primeneniya tsitikolina u patsiyentov s postinsul’tnymi kognitivnymi narusheniyami. Nevrologiya, Neyropsikhiatriya, Psikhosomatika. 2020;12(4):43-48. (In Russ.). https://doi.org/10.14412/2074-2711-2020-4-43-48
Voznyuk IA, Zavadenko NN, Kamchatnov PR, et al. The results of the round table: modern approaches to drug therapy of cognitive impairment in cerebrovascular pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8):147-152. (In Russ.). https://doi.org/10.17116/jnevro2021121081147
Kuznetsova SM, Cherska MS. Clinical aspects of the use neuroprotectors in patients with chronic cerebrovascular diseases and diabetes mellitus. The Scientific Heritage. 2020;54-2(54):60-68. (In Russ).
Bogolepova AN, Vasenina EE, Gomzyakova NA, et al. Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10-3):6-137. (In Russ.). https://doi.org/10.17116/jnevro20211211036
Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131-137. https://doi.org/10.2147/CIA.S38420
Alvarez-Sabin J, Ortega G, Jacas C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis. 2013;35(2):146-154. https://doi.org/10.1159/000346602
Cohen RA, Browndyke JN, Moser DJ, et al. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. Cerebrovasc Dis. 2003;16(3):199-204. https://doi.org/10.1159/000071116
Shestakova MV, Alekhin DI, Kokorishvili MA, et al. Citicoline treatment in reconstructive operations of carotid arteries for prevention of reperfusion complications and cognitive disturbances in patients at risk. Neurological Journal. 2014;19(2):47-52. (In Russ.).
Halushko OA. Neuroprotection in diabetic patients with acute stroke. Emergency Medicine. 2017;8(87):87-92. (In Russ.). https://doi.org/10.22141/2224-0586.8.87.2017.121329

Close metadata